research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
Search
for
Sort by
Research
840-870 / 1000+ results research Polymeric Micelle Nanocarriers for the Cutaneous Delivery of Tacrolimus: A Targeted Approach for the Treatment of Psoriasis
New micelle nanocarriers deliver Tacrolimus more effectively to skin layers for psoriasis treatment than the current Protopic ointment.
research A Review of the Efficacy and Safety Profile of Oral Spironolactone Use for Androgenic Alopecia -Supplemental Text
research Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study
Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
research Strengthening hair with Centella asiatica: a report of clinical and subjective efficacy of a local treatment with a 0.5% hair lotion
A lotion with Centella asiatica extract reduced hair loss by 41% and increased hair strength without side effects.
research Porokeratotic adnexal ostial naevus: review on the entity and therapeutic approach
Laser treatments are the most effective for porokeratotic adnexal ostial nevus.
research Ionic liquid–coated Eudragit RS nanoparticles for topical delivery of honokiol to remodel the hair follicle microenvironment in androgenic alopecia
research Preparation and Evaluation of Topical Formulation of Diphenylcyclopropenone for the Treatment of Alopecia Areata
Method B with propylene glycol is better for stable low-concentration DPCP solutions for alopecia areata.
research Botulinum Toxin A Delivery via MMP Technique: An Emerging Therapeutic Approach for Frontal Fibrosing Alopecia
Botulinum Toxin Type A delivered through the skin may be a promising treatment for Frontal Fibrosing Alopecia.
research Clinical positioning and future prospects of JAK inhibitors in alopecia areata
JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.
research Subsurface detection of hair follicles in alopecia areata using optical coherence tomography
OCT can detect hidden hair follicles in alopecia areata, indicating potential hair regrowth.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Transepidermal drug delivery: A new treatment option for areata alopecia?
Transepidermal drug delivery effectively treated areata alopecia with minimal side effects.
research P79: Efficacy of baricitinib in adults with alopecia areata: patients’ perspectives on hair regrowth from two phase III randomized controlled trials (BRAVE‐AA1 and BRAVE‐AA2)
Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Therapeutic Effect of Superficial Cryotherapy versus Intralesional Corticosteroids injection in Alopecia Areata
TCA injections are more effective and safer than cryotherapy for treating alopecia areata.
research Overview of alopecia areata for managed care and payer stakeholders in the United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
research Consensus on the treatment of alopecia areata – Brazilian Society of Dermatology
Tailored treatments for alopecia areata are recommended based on severity and patient needs.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
research European expert consensus statement on the systemic treatment of alopecia areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
Experts recommend personalized treatment plans for alopecia areata, using corticosteroids and minoxidil for mild cases, and stronger medications for severe cases.
research Latanoprost and minoxidil: Comparative double-blind, placebo-controlled study for the treatment of hair loss
Latanoprost and minoxidil effectively control hair loss and increase hair count.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Intralesional steroids for alopecia areata
Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.
research The Effect of Topical Bimatoprost 0.03% Solution on Androgenic Alopecia
Bimatoprost 0.03% solution may help treat hair loss.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research A study to compare the efficacy and safety of platelet rich plasma and topical minoxidil fortified with finasteride in the treatment of androgenic alopecia in male patients
Both treatments were equally effective in promoting hair growth.
research Fe de errores
The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.